Prolonged survival after neoadjuvant chemotherapy related with specific molecular alterations in the patients with nonsmall-cell lung carcinoma
2015
Аутори:
Stojsic, JelenaStankovic, Tijana
Stojković Burić, Sonja
Milinkovic, Vedrana
Dinić, Jelena
Milosevic, Zorica
Milovanovic, Zorka
Tanić, Nikola
Banković, Jasna Z.
Тип документа:
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт:
Lung cancer is the most common cause of neoplasia-related death
worldwide. Accounting for approximately 80\% of all lung carcinomas, the
non-small cell lung carcinoma (NSCLC) is the most common clinical form
with its two predominant histological types, adenocarcinoma (ADC) and
squamous cell carcinoma (SCC). Although surgical resection is the most
favorable treatment for patients with NSCLC, relapse is still high, so
neoadjuvant chemotherapy (NAC) is an accepted treatment modality. In
this study we examined whether some of the key molecules associated with
the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways could have
predictive and prognostic value for the NAC application. To that end we
examined the expression status of PTEN, pAKT, pERK and loss of
heterozygosity (LOH) of PTEN in two groups of NSCLC patients, those who
received and those who did not receive NAG LOH PTEN and low pERK
expression is shown to be correlated with the longest survival of
patients with SCC and ADC, respectively, who received NAC. These results
point that the application of NAC is beneficial in the NSCLC patients
with specific molecular alterations which could further help to improve
constant search for the druggable molecular targets used in personalized
therapy. (C) 2014 Elsevier Inc. All rights reserved.
Кључне речи:
Non-small cell lung carcinoma; Neodjuvant chemotherapyИзвор:
Experimental and Molecular Pathology, 2015, 98, 1, 27-32
DOI: 10.1016/j.yexmp.2014.11.010
ISSN: 1096-0945